{"entity": "researcher", "timestamp": "2026-08-22T08:38:37.620Z", "family": "Oroujeni", "given": "Maryam", "initials": "M", "orcid": "0000-0003-2660-9837", "affiliations": ["Department of Immunology, Genetics and Pathology, Uppsala University, 752 37 Uppsala, Sweden.", "Affibody AB, 171 65 Solna, Sweden."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/8bdd7a76401c42b4bbe8b11cfdb83212.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/8bdd7a76401c42b4bbe8b11cfdb83212"}}, "publications": [{"entity": "publication", "iuid": "8dd62b52564244adb5b31b41d3dad8c8", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/8dd62b52564244adb5b31b41d3dad8c8.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/8dd62b52564244adb5b31b41d3dad8c8"}}, "title": "Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA).", "authors": [{"family": "Bezverkhniaia", "given": "Ekaterina", "initials": "E", "orcid": "0000-0001-7699-5719", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/211d24252bc84d43aed1d7ed4c3d3238.json"}}, {"family": "Kanellopoulos", "given": "Panagiotis", "initials": "P", "orcid": "0000-0002-0617-3936", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/85ce3df2ffae4754946f11bb2e98ef97.json"}}, {"family": "Abouzayed", "given": "Ayman", "initials": "A"}, {"family": "Larkina", "given": "Mariia", "initials": "M", "orcid": "0000-0003-1176-2441", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/557c8a9c8b2142a7a88d6211335d24e4.json"}}, {"family": "Oroujeni", "given": "Maryam", "initials": "M", "orcid": "0000-0003-2660-9837", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8bdd7a76401c42b4bbe8b11cfdb83212.json"}}, {"family": "Vorobyeva", "given": "Anzhelika", "initials": "A", "orcid": "0000-0002-4778-3909", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/99703faa11ab4c19aff2f426f61c3134.json"}}, {"family": "Rosenstr\u00f6m", "given": "Ulrika", "initials": "U", "orcid": "0000-0002-0817-8140", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/ec6820fcb786475d85969630b0b3860b.json"}}, {"family": "Tolmachev", "given": "Vladimir", "initials": "V", "orcid": "0000-0002-6122-1734", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/896ae9fae8b74251afe11b4354c62794.json"}}, {"family": "Orlova", "given": "Anna", "initials": "A", "orcid": "0000-0001-6120-2683", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1c374f429702489494c05f84f298b4b7.json"}}], "type": "journal article", "published": "2023-12-12", "journal": {"title": "Int J Mol Sci", "issn": "1422-0067", "volume": "24", "issue": "24", "issn-l": null}, "abstract": "Radionuclide imaging using radiolabeled inhibitors of prostate-specific membrane antigen (PSMA) can be used for the staging of prostate cancer. Previously, we optimized the Glu-urea-Lys binding moiety using a linker structure containing 2-napththyl-L-alanine and L-tyrosine. We have now designed a molecule that contains mercaptoacetyl-triglutamate chelator for labeling with Tc-99m (designated as BQ0413). The purpose of this study was to evaluate the imaging properties of [99mTc]Tc-BQ0413. PSMA-transfected PC3-pip cells were used to evaluate the specificity and affinity of [99mTc]Tc-BQ0413 binding in vitro. PC3-pip tumor-bearing BALB/C nu/nu mice were used as an in vivo model. [99mTc]Tc-BQ0413 bound specifically to PC3-pip cells with an affinity of 33 \u00b1 15 pM. In tumor-bearing mice, the tumor uptake of [99mTc]Tc-BQ0413 (38 \u00b1 6 %IA/g in PC3-pip 3 h after the injection of 40 pmol) was dependent on PSMA expression (3 \u00b1 2 %IA/g and 0.9 \u00b1 0.3 %IA/g in PSMA-negative PC-3 and SKOV-3 tumors, respectively). We show that both unlabeled BQ0413 and the commonly used binder PSMA-11 enable the blocking of [99mTc]Tc-BQ0413 uptake in normal PSMA-expressing tissues without blocking the uptake in tumors. This resulted in an appreciable increase in tumor-to-organ ratios. At the same injected mass (5 nmol), the use of BQ0413 was more efficient in suppressing renal uptake than the use of PSMA-11. In conclusion, [99mTc]Tc-BQ0413 is a promising probe for the visualization of PSMA-positive lesions using single-photon emission computed tomography (SPECT).", "doi": "10.3390/ijms242417391", "pmid": "38139219", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC10743726"}, {"db": "pii", "key": "ijms242417391"}], "notes": [], "created": "2026-08-21T13:03:48.635Z", "modified": "2026-08-21T13:03:48.835Z"}, {"entity": "publication", "iuid": "658dcf32f8274f2caf86feccdd64ae49", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/658dcf32f8274f2caf86feccdd64ae49.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/658dcf32f8274f2caf86feccdd64ae49"}}, "title": "The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy.", "authors": [{"family": "Yin", "given": "Wen", "initials": "W"}, {"family": "Xu", "given": "Tianqi", "initials": "T", "orcid": "0000-0002-1826-4093", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/688f685bf3474e72bfab58e1fa2035b9.json"}}, {"family": "Altai", "given": "Mohamed", "initials": "M"}, {"family": "Oroujeni", "given": "Maryam", "initials": "M", "orcid": "0000-0003-2660-9837", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8bdd7a76401c42b4bbe8b11cfdb83212.json"}}, {"family": "Zhang", "given": "Jie", "initials": "J", "orcid": "0000-0002-4472-3468", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/2b392e01b09d47e28f284d6f45e5bd93.json"}}, {"family": "Vorobyeva", "given": "Anzhelika", "initials": "A", "orcid": "0000-0002-4778-3909", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/99703faa11ab4c19aff2f426f61c3134.json"}}, {"family": "Vorontsova", "given": "Olga", "initials": "O"}, {"family": "Vtorushin", "given": "Sergey V", "initials": "SV"}, {"family": "Tolmachev", "given": "Vladimir", "initials": "V", "orcid": "0000-0002-6122-1734", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/896ae9fae8b74251afe11b4354c62794.json"}}, {"family": "Gr\u00e4slund", "given": "Torbj\u00f6rn", "initials": "T", "orcid": "0000-0002-5391-600X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/afff2431691348539334ab0e86158505.json"}}, {"family": "Orlova", "given": "Anna", "initials": "A", "orcid": "0000-0001-6120-2683", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1c374f429702489494c05f84f298b4b7.json"}}], "type": "journal article", "published": "2021-11-21", "journal": {"title": "Pharmaceutics", "issn": "1999-4923", "volume": "13", "issue": "11", "issn-l": null}, "abstract": "Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the influence of the number and positioning of the protein domains in the drug conjugate. Seven HER2-targeting affibody-based constructs, including one or two affibody molecules (Z) with or without an albumin-binding domain (ABD), namely Z, Z-ABD, ABD-Z, Z-Z, Z-Z-ABD, Z-ABD-Z, and ABD-Z-Z, were evaluated on their effects on cell growth, in vivo targeting, and biodistribution. The biodistribution study demonstrated that the monomeric constructs had longer blood retention and lower hepatic uptake than the dimeric ones. A dimeric construct, specifically ABD-Z-Z, could stimulate the proliferation of HER2 expressing SKOV-3 cells in vitro and the growth of tumors in vivo, whereas the monomeric construct Z-ABD could not. These two constructs demonstrated a therapeutic effect when coupled to mcDM1; however, the effect was more pronounced for the non-stimulating Z-ABD. The median survival of the mice treated with Z-ABD-mcDM1 was 63 days compared to the 37 days for those treated with ABD-Z-Z-mcDM1 or for the control animals. Domain permutation of an ABD-fused HER2-targeting affibody-based drug conjugate significantly influences tumor cell proliferation and therapy efficacy. The monomeric conjugate Z-ABD is the most promising format for targeted delivery of the cytotoxic drug DM1.", "doi": "10.3390/pharmaceutics13111974", "pmid": "34834389", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC8617914"}, {"db": "pii", "key": "pharmaceutics13111974"}], "notes": [], "created": "2026-08-21T13:04:54.714Z", "modified": "2026-08-21T13:04:54.844Z"}, {"entity": "publication", "iuid": "308000414b404416baa5cb9c4f699492", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/308000414b404416baa5cb9c4f699492.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/308000414b404416baa5cb9c4f699492"}}, "title": "Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart.", "authors": [{"family": "Oroujeni", "given": "Maryam", "initials": "M", "orcid": "0000-0003-2660-9837", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/8bdd7a76401c42b4bbe8b11cfdb83212.json"}}, {"family": "Abouzayed", "given": "Ayman", "initials": "A"}, {"family": "Lundmark", "given": "Fanny", "initials": "F"}, {"family": "Mitran", "given": "Bogdan", "initials": "B"}, {"family": "Orlova", "given": "Anna", "initials": "A", "orcid": "0000-0001-6120-2683", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1c374f429702489494c05f84f298b4b7.json"}}, {"family": "Tolmachev", "given": "Vladimir", "initials": "V", "orcid": "0000-0002-6122-1734", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/896ae9fae8b74251afe11b4354c62794.json"}}, {"family": "Rosenstr\u00f6m", "given": "Ulrika", "initials": "U"}], "type": "journal article", "published": "2019-08-02", "journal": {"title": "Pharmaceutics", "issn": "1999-4923", "volume": "11", "issue": "8", "issn-l": null}, "abstract": "Radiolabelled antagonistic bombesin analogues are successfully used for targeting of gastrin-releasing peptide receptors (GRPR) that are overexpressed in prostate cancer. Internalization of antagonistic bombesin analogues is slow. We hypothesized that the use of a non-residualizing radioiodine label might not affect the tumour uptake but would reduce the retention in normal organs, where radiopharmaceutical would be internalized. To test this hypothesis, tyrosine was conjugated via diethylene glycol linker to N-terminus of an antagonistic bombesin analogue RM26 to form Tyr-PEG2-RM26. [111In]In-DOTA-PEG2-RM26 was used as a control with a residualizing label. Tyr-PEG2-RM26 was labelled with 125I with 95% radiochemical purity and retained binding specificity to GRPR. The IC50 values for Tyr-PEG2-RM26 and DOTA-PEG2-RM26 were 1.7 \u00b1 0.3 nM and 3.3 \u00b1 0.5 nM, respectively. The cellular processing of [125I]I-Tyr-PEG2-RM26 by PC-3 cells showed unusually fast internalization. Biodistribution showed that uptake in pancreas and tumour was GRPR-specific for both radioconjugates. Blood clearance of [125I]I-Tyr-PEG2-RM26 was appreciably slower and activity accumulation in all organs was significantly higher than for [111In]In-DOTA-PEG2-RM26. Tumor uptake of [111In]In-DOTA-PEG2-RM26 was significantly higher than for [125I]I-Tyr-PEG2-RM26, resulting in higher tumour-to-organ ratio for [111In]In-DOTA-PEG2-RM26 at studied time points. Incorporation of amino acids with hydrophilic side-chains next to tyrosine might overcome the problems associated with the use of tyrosine as a prosthetic group for radioiodination.", "doi": "10.3390/pharmaceutics11080380", "pmid": "31382362", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6724035"}, {"db": "pii", "key": "pharmaceutics11080380"}], "notes": [], "created": "2026-08-21T13:04:40.539Z", "modified": "2026-08-21T13:04:40.593Z"}]}